$VYGR
Voyager Therapeutics Inc

2024 Q2 Form 10-Q Financial Statement

#000155837024007953 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $29.60M $19.50M
YoY Change 509.93% -87.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.15M $8.607M
YoY Change 22.39% -4.66%
% of Gross Profit
Research & Development $34.45M $27.09M
YoY Change 56.71% 45.91%
% of Gross Profit
Depreciation & Amortization $1.392M $1.196M
YoY Change 28.18% 11.26%
% of Gross Profit
Operating Expenses $44.60M $35.70M
YoY Change 47.31% 29.36%
Operating Profit -$15.03M -$16.18M
YoY Change -40.91% -113.17%
Interest Expense $4.888M $4.867M
YoY Change 49.3% 161.11%
% of Operating Profit
Other Income/Expense, Net $4.908M $4.867M
YoY Change 163500.0% 161.11%
Pretax Income -$10.12M -$11.32M
YoY Change -54.32% -109.07%
Income Tax $24.00K $14.00K
% Of Pretax Income
Net Earnings -$10.14M -$11.33M
YoY Change -54.34% -109.13%
Net Earnings / Revenue -34.26% -58.1%
Basic Earnings Per Share -$0.18 -$0.20
Diluted Earnings Per Share -$0.18 -$0.20
COMMON SHARES
Basic Shares Outstanding 54.39M 54.30M
Diluted Shares Outstanding 57.72M 57.12M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $371.0M $399.6M
YoY Change 36.03% 46.19%
Cash & Equivalents $76.13M $143.1M
Short-Term Investments $294.9M $256.5M
Other Short-Term Assets $7.298M $6.112M
YoY Change 20.03% 53.45%
Inventory
Prepaid Expenses
Receivables $3.251M $3.457M
Other Receivables $0.00 $0.00
Total Short-Term Assets $381.6M $409.1M
YoY Change 35.22% 35.2%
LONG-TERM ASSETS
Property, Plant & Equipment $16.27M $17.38M
YoY Change -48.79% 1.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $980.0K
YoY Change
Other Assets $2.874M $2.890M
YoY Change 80.41% 90.76%
Total Long-Term Assets $54.66M $60.46M
YoY Change 63.83% 79.56%
TOTAL ASSETS
Total Short-Term Assets $381.6M $409.1M
Total Long-Term Assets $54.66M $60.46M
Total Assets $436.2M $469.6M
YoY Change 38.25% 39.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.605M $7.579M
YoY Change 57.02% 104.95%
Accrued Expenses $10.27M $7.595M
YoY Change -14.91% -0.58%
Deferred Revenue $20.52M $51.44M
YoY Change -35.21% 805.62%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $40.13M $72.55M
YoY Change -11.6% 263.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.21M $43.00M
YoY Change -42.06% 109.51%
Total Long-Term Liabilities $41.21M $43.00M
YoY Change -42.06% 109.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.13M $72.55M
Total Long-Term Liabilities $41.21M $43.00M
Total Liabilities $100.8M $128.7M
YoY Change -13.48% 7.85%
SHAREHOLDERS EQUITY
Retained Earnings -$282.7M -$272.5M
YoY Change -3.09% 1.11%
Common Stock $54.00K $54.00K
YoY Change 22.73% 25.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $335.4M $340.9M
YoY Change
Total Liabilities & Shareholders Equity $436.2M $469.6M
YoY Change 38.25% 39.64%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$10.14M -$11.33M
YoY Change -54.34% -109.13%
Depreciation, Depletion And Amortization $1.392M $1.196M
YoY Change 28.18% 11.26%
Cash From Operating Activities -$31.58M $58.77M
YoY Change 3682.04% -52.44%
INVESTING ACTIVITIES
Capital Expenditures $967.0K $2.141M
YoY Change -20.08% 320.63%
Acquisitions
YoY Change
Other Investing Activities -$34.98M -$93.92M
YoY Change 49.13% -726.16%
Cash From Investing Activities -$35.94M -$96.07M
YoY Change 45.74% -762.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 571.0K 112.9M
YoY Change -63.11% 260.49%
NET CHANGE
Cash From Operating Activities -31.58M 58.77M
Cash From Investing Activities -35.94M -96.07M
Cash From Financing Activities 571.0K 112.9M
Net Change In Cash -66.95M 75.56M
YoY Change 179.55% -55.39%
FREE CASH FLOW
Cash From Operating Activities -$31.58M $58.77M
Capital Expenditures $967.0K $2.141M
Free Cash Flow -$32.55M $56.63M
YoY Change 1491.54% -53.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2023Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2023Q1 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://www.voyagertherapeutics.com/20240331#DepositsAndOtherNonCurrentAssets
CY2024Q1 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://www.voyagertherapeutics.com/20240331#DepositsAndOtherNonCurrentAssets
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001640266
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44038333
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54318133
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37625
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
75 Hayden Avenue
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
CY2024Q1 dei City Area Code
CityAreaCode
857
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
259-5340
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
VYGR
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54393628
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143078000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68802000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
256490000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
162073000
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
837000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
80150000
CY2024Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2620000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3341000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6112000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5318000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
409137000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
319684000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17381000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16494000
CY2024Q1 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
2890000
CY2023Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1593000
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
980000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39204000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13510000
CY2024Q1 us-gaap Assets
Assets
469592000
CY2023Q4 us-gaap Assets
Assets
351281000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7579000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1604000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7595000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16823000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5940000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3200000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51439000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
42881000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
72553000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64508000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13157000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32359000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42996000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18094000
CY2024Q1 us-gaap Liabilities
Liabilities
128706000
CY2023Q4 us-gaap Liabilities
Liabilities
114961000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54318133
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44038333
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
54000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
613850000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
497506000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-506000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272512000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261182000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
340886000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
236320000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469592000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
351281000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19516000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150480000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27092000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18568000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8607000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9028000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
35699000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
27596000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16183000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
122884000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4867000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1864000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4867000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1864000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11316000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
124748000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
704000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11330000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
124044000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-458000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-458000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-683000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10643000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18725000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
58767000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
123565000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2141000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
509000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
87000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11788000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
124131000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.94
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57117046
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40632087
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57117046
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42161326
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2504000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
124044000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216961000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
236320000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2024Q1 vygr Stock And Pre Funded Warrants Issued During Period Value New Issues
StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues
93473000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-458000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11330000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
340886000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-11330000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
124044000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3573000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2558000
CY2024Q1 us-gaap Depreciation
Depreciation
1196000
CY2023Q1 us-gaap Depreciation
Depreciation
1075000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1931000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
17000
CY2024Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-59000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-44000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-79313000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25000000
CY2024Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-721000
CY2023Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
71000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
794000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1411000
CY2024Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-1057000
CY2023Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-469000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
15000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5975000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1132000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9305000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-122000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
891000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
203852000
CY2024Q1 vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
109928000
CY2023Q1 vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
15000000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96065000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14491000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
78000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
185000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93473000
CY2024Q1 vygr Proceeds From Issuance Of Common Stock In Connection With2023 Novartis Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWith2023NovartisCollaborationAgreement
19305000
CY2023Q1 vygr Proceeds From Issuance Of Common Stock In Connection With2023 Neurocrine Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWith2023NeurocrineCollaborationAgreement
31121000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112856000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31306000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75558000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
169362000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70395000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100474000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145953000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
269836000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
CY2024Q1 vygr Lease Exchange Cash Flow Amount
LeaseExchangeCashFlowAmount
26751000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease; amyotrophic lateral sclerosis; Parkinson’s disease, and multiple other diseases of the central nervous system. Many of the Company’s programs are derived from its TRACER™ adeno-associated virus (“AAV”) capsid discovery platform, which the Company has used to generate novel capsids (“TRACER Capsids”) and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the Company’s programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG, (“Novartis”); and Neurocrine Biosciences, Inc. (“Neurocrine”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a history of incurring annual net operating losses. As of March 31, 2024, the Company had an accumulated deficit of $272.5 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities, funding from fees, option exercise payments, and milestone payments, and cost reimbursements associated with its prior and ongoing collaborations and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March 31, 2024, the Company had cash, cash equivalents, and marketable securities of $400.5 million. Based upon the Company’s current operating plans, the Company expects that its existing cash, cash equivalents, and marketable securities at March 31, 2024 to be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272500000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
400500000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2024Q1 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
306305000
CY2024Q1 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
19000
CY2024Q1 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
390000
CY2024Q1 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
305934000
CY2023Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
227583000
CY2023Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
93000
CY2023Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
13000
CY2023Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
227663000
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1000000.0
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
230700000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
44200000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143078000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268321000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
2875000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1515000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145953000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
269836000
CY2024Q1 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2914000
CY2023Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5225000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2248000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6614000
CY2024Q1 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1838000
CY2023Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
4229000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
595000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
755000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7595000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16823000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2024Q1 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.069
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5940000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3200000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5940000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3200000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41995000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17093000
CY2024Q1 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2023Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42996000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18094000
CY2024Q1 vygr Number Of New Collaborations Or License Agreements
NumberOfNewCollaborationsOrLicenseAgreements
0
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19500000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150500000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3573000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2558000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3573000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2558000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7425444
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.52
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1747626
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.68
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
32500
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.91
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
230974
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.28
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8909596
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.27
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17875000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3880357
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.04
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8728000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10651434
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8741904
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11330000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
124044000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57117046
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40632087
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57117046
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40632087
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1529239
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57117046
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42161326
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.94

Files In Submission

Name View Source Status
0001558370-24-007953-index-headers.html Edgar Link pending
0001558370-24-007953-index.html Edgar Link pending
0001558370-24-007953.txt Edgar Link pending
0001558370-24-007953-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20240331.xsd Edgar Link pending
vygr-20240331x10q.htm Edgar Link pending
vygr-20240331x10q006.jpg Edgar Link pending
vygr-20240331xex10d1.htm Edgar Link pending
vygr-20240331xex10d4.htm Edgar Link pending
vygr-20240331xex31d1.htm Edgar Link pending
vygr-20240331xex31d2.htm Edgar Link pending
vygr-20240331xex32d1.htm Edgar Link pending
vygr-20240331_cal.xml Edgar Link unprocessable
vygr-20240331_def.xml Edgar Link unprocessable
vygr-20240331_lab.xml Edgar Link unprocessable
vygr-20240331_pre.xml Edgar Link unprocessable
vygr-20240331x10q_htm.xml Edgar Link completed